Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - ammonium chloride dextromethorphan ipecacuanha fluid extract phenylephrine hydrochloride -

United States - English - NLM (National Library of Medicine)

nnodum pharmaceuticals - ammonium lactate (unii: 67m901l9nq) (lactic acid - unii:33x04xa5at) - ammonium lactate 17 g in 1 g - ammonium lactate cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. ammonium lactate cream is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

United States - English - NLM (National Library of Medicine)

nnodum pharmaceuticals - ammonium lactate (unii: 67m901l9nq) (lactic acid - unii:33x04xa5at) - ammonium lactate 17 g in 1 g - ammonium lactate lotion is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. ammonium lactate lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 87.2 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; sucrose; titanium dioxide; indigo carmine; ammonium chloride; sodium starch glycollate type b; lactose monohydrate; gelatin; macrogol 6000; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 65.4 mg - capsule, hard - excipient ingredients: sodium starch glycollate type b; titanium dioxide; sucrose; macrogol 6000; indigo carmine; gelatin; sodium lauryl sulfate; ammonium chloride; purified water; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 43.6 mg - capsule, hard - excipient ingredients: macrogol 6000; ammonium chloride; lactose monohydrate; purified water; titanium dioxide; sucrose; gelatin; sodium starch glycollate type b; sodium lauryl sulfate; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 21.8 mg - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; sodium starch glycollate type b; purified water; sucrose; titanium dioxide; ammonium chloride; sodium lauryl sulfate; indigo carmine; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 87.2 mg - capsule, hard - excipient ingredients: macrogol 6000; titanium dioxide; lactose monohydrate; sodium starch glycollate type b; gelatin; ammonium chloride; indigo carmine; sodium lauryl sulfate; purified water; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 65.4 mg - capsule, hard - excipient ingredients: titanium dioxide; sucrose; macrogol 6000; purified water; lactose monohydrate; ammonium chloride; indigo carmine; sodium lauryl sulfate; sodium starch glycollate type b; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 43.6 mg - capsule, hard - excipient ingredients: sodium starch glycollate type b; titanium dioxide; indigo carmine; lactose monohydrate; purified water; macrogol 6000; ammonium chloride; sucrose; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.